Renalytix PLC (RNLXY) intrinsic value & 10-year financials
Renalytix PLC (RNLXY) has a Graham intrinsic value of $4.26 per share. At $3.50 on Oct 17, 2026, the stock trades 18% below that value. Over the last 4 fiscal years revenue shrank 12.2% a year to $2.3M, with an average return on invested capital of 329.7%.
- Graham intrinsic value
- $4.26
- Share price (Oct 17, 2026)
- $3.50
- Price vs Graham value
- 18% below
- Market cap
- $378.6M
- Revenue (FY2024)
- $2.3M
- Revenue growth (4-yr CAGR)
- -12.2%
- ROIC (10-yr avg)
- 329.7%
- Free cash flow (FY2024)
- —
RNLXY 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2024 | $2.3M | -$33.5M | -$0.31 | — | -1293.5% | 196.0% |
| FY2023 | $100.0K | -$45.6M | -$0.55 | -$34.1M | -42221.0% | 297.3% |
| FY2022 | $3.0M | -$45.3M | -$0.67 | -$46.5M | -1790.7% | 495.8% |
| FY2021 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Renalytix plc revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Renalytix plc has historically struggled to out-earn its cost of capital, averaging just 3.3% ROIC.
Renalytix plc capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Renalytix plc is modeled at -12.2% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $4.26 per share.